Search
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form. … Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome.
Huperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnThe botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. … It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.
Categories: Compounds used in a research, industrial, or household settingVanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations.
Synonyms: VX-121Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies.
Categories: Sensitizers Used in Photodynamic/radiation Therapy, Heterocyclic Compounds with 4 or More RingsEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.
Mixtures: Synjardy XR, Synjardy XRCategories: Drugs Used in DiabetesFenoldopam
go.drugbank.com/drugs/DB00800ApprovedA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Categories: Antihypertensive Agents Indicated for HypertensionBrexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … for the treatment of postpartum depression (PPD) in adult females [F4066].
Foreskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedDermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … If wound closure is achieved, it is likely to delay the need for surgical intervention and provide other benefits such as improvements in productivity, mental outlook, social interactions, and time at
Gallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer. … In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Ga-68 gozetotide be granted marketing authorization for the diagnosis of prostate cancer.
Synonyms: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CCCategories: Compounds used in a research, industrial, or household settingZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigational[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. … The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
Categories: Compounds used in a research, industrial, or household setting, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates